Funding: Halt raises $15M to commercialize its device to treat uterine fibroids

January 8, 2013 by MassDevice staff

Halt Medical closes $15 million financing from American Capital to support commercialization of its newly FDA cleared Acessa System, an alternative to hysterectomy for women with uterine fibroids.

Halt logo

Halt Medical closed a $15 million funding round from American Capital, aimed at commercializing its FDA-cleared Acessa System for treating uterine fibroids.

The Las Vegas, Nev.-based device maker said its Acessa system allows physicians to deliver radiofrequency energy to uterine fibroids through a minimally invasive procedure.

Sign up to get our free newsletters delivered right to your inbox.

"We are delighted that American Capital, has chosen to once again lead financing for this critical new medical device,"Halt's CEO Jeff Cohen said in prepared remarks. "Furthermore, there was significant participation by existing investors, validating our work to address one of the largest unmet needs in women's health worldwide."

Last November, the FDA cleared Acessa system , the 1st product cleared, which can be used by gynecologists to treat all fibroid symptoms and type, the company said.

Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control.

In traditional fibroid surgery, a physician generally must either cut through healthy tissue to access the tumor or remove the uterus entirely, according to Halt Medical.